Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.
Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.
复制标题
DOI：
10.3390/vaccines1030328
复制
发表时间：
2013-08-09
期刊：
影响因子：
7.8
通讯作者：
Fernandez S
中科院分区：
文献类型：
--
作者：
French MA;Abudulai LN;Fernandez S
治疗和预防人类免疫缺陷病毒（HIV）感染的疫苗的开发由于对针对HIV的“保护性”免疫应答的不完全理解而受到阻碍。HIV-1感染的自然控制与针对HIV-1 Gag蛋白的T细胞应答相关，特别是受“保护性”HLA-B等位基因限制的CD 8 + T细胞应答，但其他免疫应答也有助于免疫控制。这些免疫应答似乎包括针对HIV-1 Gag蛋白的IgG抗体、干扰素-α-依赖性自然杀伤（NK）细胞应答和浆细胞样树突细胞（pDC）应答。这里，提出了针对HIV-1 Gag蛋白的IgG抗体的同种型多样化，包括IgG 2以及IgG 3和IgG 1抗体，将拓宽抗体应答的功能，并促进NK细胞和pDC针对HIV-1的辅助细胞应答。我们建议将其作为HIV-1感染的疫苗接种策略进行研究。
The development of vaccines to treat and prevent human immunodeficiency virus (HIV) infection has been hampered by an incomplete understanding of “protective” immune responses against HIV. Natural control of HIV-1 infection is associated with T-cell responses against HIV-1 Gag proteins, particularly CD8+ T-cell responses restricted by “protective” HLA-B alleles, but other immune responses also contribute to immune control. These immune responses appear to include IgG antibodies to HIV-1 Gag proteins, interferon-α-dependant natural killer (NK) cell responses and plasmacytoid dendritic cell (pDC) responses. Here, it is proposed that isotype diversification of IgG antibodies against HIV-1 Gag proteins, to include IgG2, as well as IgG3 and IgG1 antibodies, will broaden the function of the antibody response and facilitate accessory cell responses against HIV-1 by NK cells and pDCs. We suggest that this should be investigated as a vaccination strategy for HIV-1 infection.